BGC
BMY icon

Blue Granite Capital’s Bristol-Myers Squibb BMY Stock Holding History

Blue Granite Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,141
Closed -$583K – 112
2017
Q3 		$583K Buy
+9,141
New +$534K 0.4% 72

Other funds holding BMY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Blue Granite Capital's BMY Position: Q4 2017 in Review

Blue Granite Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2017, closing a stake of 9,141 shares — an estimated $583K sold.

Blue Granite Capital first reported a position in BMY in Q3 2017 and held it in 1 quarter. The position peaked at $583K in Q3 2017. 1,735 funds tracked by Wall St. Rank hold BMY as of Q4 2017.

  • Blue Granite Capital reported no remaining Bristol-Myers Squibb position as of Q4 2017 after selling out during the quarter.
  • Blue Granite Capital sold 9,141 Bristol-Myers Squibb shares in Q4 2017, an estimated $583K.
  • Blue Granite Capital first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 1 quarter.
  • Blue Granite Capital's Bristol-Myers Squibb position peaked at $583K in Q3 2017.
  • 1,735 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2017.

Based on Blue Granite Capital's 13F filing for Q4 2017, filed 14 Feb 2018.